BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• 

  Business

  Candel Pairs HSV Vectors with Carl June’s CAR-T Cells in Solid Tumor Pact (Updated)

  Candel revealed a collaboration with the University of Pennsylvania to assess the combination of Candel’s viral immunotherapy and UPenn’s CAR-T cell treatments in solid tumor models.

  October 27, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Movers & Shakers: Adaptive Phage, Atossa, Nimbus and more

  New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.

  October 27, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  DiaMedica Ischemic Stroke Program Remains on Hold with Plans for Additional Studies

  Minneapolis-based DiaMedica Therapeutics plans to conduct additional studies in order to resolve a clinical hold on its DM199 program for the treatment of acute ischemic stroke (AIS).

  October 27, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  FDA Keeps Jazz’s SCLC Treatment on the Market Despite Failed Confirmatory Trial

  The FDA has upheld the accelerated approval of Jazz Pharmaceuticals’ Zepzelca (lurbinectedin), even though the drug failed to reach its primary endpoint in the confirmatory Phase III ATLANTIS trial.

  October 27, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  GSK Pulls Plug on Investigational RA Drug Following Trial Failure

  GSK is pulling the plug on an experimental monoclonal antibody therapy for rheumatoid arthritis following a significant miss in one of three Phase III trials.

  October 27, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Bone Fixes Fracture with “Synergistic” Reverse Merger, Becomes BioSenic

  Struggling Bone Therapeutics may have caught a break. The cell therapy company is rebranding with the name BioSenic following a reverse merger with France’s Medsenic that closed Tuesday.

  October 27, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations

  Scorpion Therapeutics is on a mission to create a world where many more cancer patients can benefit from precision therapies. Earlier this year, it struck a $75 million alliance with AstraZeneca.

  October 27, 2022

   · 

  7 min read

   · 

  BioSpace Staff
• 

  Drug Development

  Roche’s Vabysmo Matches Regeneron’s Eylea in Macular Edema

  Two Phase III trials of Genentech (Roche)'s Vabysmo hit the primary endpoint in macular edema caused by branch and central retinal vein occlusion, showing non-inferiority to Regeneron’s Eylea.

  October 27, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Alnylam Opts Against Phase III Trial for Vutrisiran in Stargardt Disease - Updated

  Alnylam Pharmaceuticals released its report for Q3, in which the company stated it will no longer initiate a Phase III trial for vutrisiran in Stargardt disease.

  October 27, 2022

   · 

  3 min read

   · 

  Rosemary Scott
• 

  Business

  Harvard, MIT, FUJIFILM and More Launch Genetown Biomanufacturing Facility

  Newly-launched Massachusetts biomanufacturing facility will be something like a conveyor belt from the academic bench to the early startup.

  October 27, 2022

   · 

  3 min read

   · 

  Alex Keown